Open Outbreak

Antimicrobial resistance

Pathogen: Drug-resistant bacteria and fungi · Region: Worldwide · Status: active · Attention: elevated · Updated

OfficialMedia, unverifiedReported this week
Deaths2,318 as of 12 Nov 202639,881,000 53,200,000 highest in the last 7 days—
Confirmed cases406 as of 12 Nov 2026241,048 17 highest in the last 7 days+1 Media, unverified
Suspected cases—35,584 as of 30 Oct 2026—
Contacts under observation—302 as of 31 Dec 2025—

Official and media figures describe the same people from different vantage points and are never added together.

Antimicrobial resistance remains an active global concern, but it is not one outbreak with a single case count or transmission rate. The strongest verified updates in the 2026-11-07 to 2026-11-20 window concern England and the Americas. They describe worsening resistance over earlier reporting years, not a sudden worldwide surge during these two weeks. On 2026-11-12, UKHSA reported 21,129 antibiotic-resistant bloodstream infections in England in 2025, a 3.2% increase over 2024. The increase had slowed, and deaths among people with resistant Gram-negative bloodstream infections remained broadly level. On 2026-11-18, PAHO reported rising carbapenem resistance across participating countries in Latin America and the Caribbean. Its latest resistance estimates concern 2024, not current outbreak counts. Awareness-week reporting also highlights responses in Africa and the Eastern Mediterranean, although those articles were not independently verified here. Media coverage emphasizes large death estimates and future projections. These must not be read as deaths newly recorded in November 2026. Most collected reports remain unverified, and some extracted figures plainly do not represent infection counts. No verified new country, fungal clade, or resistant tuberculosis outbreak was established within this window. Control depends on preventing infections, testing susceptibility, using antimicrobials appropriately, and making effective medicines accessible. The main warning signs are spread between facilities or into communities, resistance to remaining treatment options, and surveillance gaps that delay detection.

Resistant infections remain widespread and can cause severe illness when standard treatment fails, while laboratory capacity and access to effective drugs are uneven. Recent official updates support persistent concern, but they do not establish rapid worldwide growth during the last two weeks; historical surveillance and mortality projections must remain separate from current case counts.

Situation as of 20 Nov 2026

Official

UKHSA's 2026-11-12 release reports 21,129 resistant bacteraemia cases in England in 2025, versus 20,468 in 2024, with growth slowing to 3.2%. It reports 2,318 deaths among people with resistant Gram-negative bacteraemia in 2025, versus 2,399 in 2024; these are not necessarily deaths attributable to resistance. PAHO's 2026-11-18 release reports carbapenem resistance in Klebsiella pneumoniae rising from approximately 15% in 2015 to 26% in 2024, based on data from 15 countries, and in Escherichia coli from 3% to 5%, based on 13 countries. Median carbapenem resistance in Acinetobacter baumannii was 77% across seven reporting countries in 2024. WHO's retrieved 2024 notice assessed resistant hypervirulent K. pneumoniae as a moderate global risk; that assessment is organism-specific and is not a new November 2026 assessment of all AMR. No current ECDC or CDC assessment was retrieved.

Media, unverified

Collected coverage from 2026-11-15 through 2026-11-18 emphasizes WHO calls for action, large worldwide mortality estimates and a projection of 39 million deaths over 25 years. Reports also describe concern in Africa and the Eastern Mediterranean. Most entries are ingestion-tier unverified, including some authority-hosted pages whose full text was not retrieved.

Control measures

PAHO describes surveillance through ReLAVRA+, stronger laboratories, timely detection, infection prevention, access to effective antibiotics and responsible prescribing, with coordination across human, animal and environmental health. World Antimicrobial Resistance Awareness Week runs from 2026-11-18 to 2026-11-24. UKHSA promotes infection prevention, vaccination and appropriate antimicrobial use under England's national action plan. Organism-specific healthcare control includes contact precautions and isolation where indicated. No global travel restriction, closure programme, or verified stockpile availability was established.

Timeline

Latest reports

  1. · premiumtimesng.com · Media, unverified
    PT Health Watch: Preventing infections key to curbing drug resistance – Experts
  2. · nannews.ng · Media, unverified
    Antimicrobial resistance threat to families, healthcare system – Expert
  3. · nannews.ng · Media, unverified
    DR-TB: NAN editor, 4 others selected for media fellowship
  4. · kenyanews.go.ke · Media, unverified
    Counties urged to tie drug resistance fight to social health insurance
  5. · capitalfm.africa · Media, unverified
    Medical professionals sound alarm over antibiotic misuse, warn of rising drug resistance
  6. · mzd.gov.cz · Media, unverified
    Publication of the Transnational OH AMR Partnership Call
  7. · PAHO news · Official
    PAHO warns of increasing resistance to antibiotics used to treat serious infections in the Americas
  8. · premiumtimesng.com · Media, unverified
    WHO calls for urgent action to curb drug resistance in Africa
  9. · emro.who.int · Media, unverified
    WHO urges coordinated action to contain antimicrobial resistance in the Eastern Mediterranean Region
  10. · emro.who.int · Media, unverified
    Call for applications: 2027 AMR Data Analysis Clinic: Building National and Facility Level Capacity to Analyse and Report AMR Surveillance Data in the WHO Eastern Mediterranean Region
  11. · kbc.co.ke · Media, unverified
    WHO warns of gaps in global fight against antimicrobial resistance
  12. · nannews.ng · Media, unverified
    WHO urges countries to translate AMR pledges into action